CureVac Soars 41% in a Month on a $1.25B Buyout Offer From BioNTech

CureVac shares surged 40.8% after BioNTech announced a definitive agreement to acquire the company for $1.25 billion in an all-stock transaction, with each CVAC share converting to $5.46 worth of BNTX ADS, representing a 55% premium. The acquisition is expected to enhance BioNTech's mRNA-based cancer immunotherapy capabilities and expand its research, development, and commercialization infrastructure, complementing its existing strengths in mRNA technology and oncology pipeline.

Analysis

CureVac N.V. (CVAC) shares experienced a significant surge, rising 40.8% in a month, following the announcement of a definitive agreement for its acquisition by BioNTech SE (BNTX) in an all-stock transaction valued at approximately $1.25 billion. According to the terms, each CVAC share will be converted into $5.46 worth of BNTX American Depositary Shares, representing a substantial 55% premium to CVAC's three-month volume-weighted average price of $3.53 as of June 11, 2025. Upon completion, expected in 2025 subject to regulatory approvals and customary closing conditions, CureVac shareholders are anticipated to hold between 4% and 6% of BioNTech. This acquisition is strategically aimed at bolstering BioNTech's capabilities in mRNA-based cancer immunotherapies by expanding its research, development, manufacturing, and commercialization infrastructure, thereby complementing its established expertise in mRNA design and delivery. Year to date, CureVac's shares have surged 61%, starkly contrasting with the industry's 4.8% decline. The transaction will also enable BioNTech to broaden its oncology focus beyond its current pipeline to include newer programs, such as its mRNA cancer candidates and BNT327, a PD-L1xVEGF-A bispecific antibody. BNTX's commitment to oncology is further underscored by its recent strategic collaboration with Bristol Myers (BMY) for BNT327, involving a $1.5 billion upfront payment, $2 billion in additional payments through 2028, and potential milestones up to $7.6 billion, with BNT327 currently in late-stage studies for lung cancer and a Phase III trial planned for breast cancer. For context within the biotech sector, the article notes that Immunocore (IMCR) holds a Zacks Rank #1 (Strong Buy), with its 2025 loss per share estimates improving from $1.50 to 86 cents and 2026 estimates narrowing from $1.68 to $1.33 in the past 60 days.

Key Decisions for Investors

• CVAC shareholders should recognize that the current stock price largely reflects the acquisition premium, with further upside contingent on the successful closing of the transaction in 2025 and the subsequent value of BNTX ADS.
• Investors in BNTX should view this acquisition as a strategic enhancement to its oncology pipeline and mRNA technology platform, while closely monitoring the integration process and clinical trial progress of newly acquired and existing key assets like BNT327.
• Biotech investors may consider the heightened M&A activity and focus on mRNA-based oncology as significant trends, evaluating opportunities in companies with strong pipelines and strategic partnerships like BioNTech, or well-regarded peers such as Immunocore, noting its improving analyst estimates and 'Strong Buy' rating.